Calamos Wealth Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$210K Buy
2,438
+141
+6% +$12.5K 0.01% 447
2026
Q2
$208K Sell
2,297
-1,466
-39% -$123K 0.01% 435
2026
Q1
$301K Sell
3,763
-198
-5% -$16.3K 0.01% 394
2025
Q4
$338K Buy
3,961
+51
+1% +$4.18K 0.01% 330
2025
Q3
$304K Buy
+3,910
New +$305K 0.01% 340
2024
Q1
– Sell
-3,166
Closed -$241K – 322
2023
Q4
$241K Sell
3,166
-1,649
-34% -$115K 0.02% 266
2023
Q3
$334K Sell
4,815
-72
-1% -$5.79K 0.03% 241
2023
Q2
$461K Buy
4,887
+1,665
+52% +$145K 0.03% 208
2023
Q1
$267K Sell
3,222
-6,200
-66% -$487K 0.02% 269
2022
Q4
$703K Sell
9,422
-52,331
-85% -$4.03M 0.05% 169
2022
Q3
$5.1M Buy
61,753
+1,047
+2% +$101K 0.44% 59
2022
Q2
$5.77M Buy
60,706
+1,492
+3% +$154K 0.51% 52
2022
Q1
$6.97M Buy
59,214
+2,318
+4% +$260K 0.52% 48
2021
Q4
$7.37M Buy
56,896
+1,118
+2% +$130K 0.54% 48
2021
Q3
$6.32M Buy
55,778
+820
+1% +$93.6K 0.51% 51
2021
Q2
$5.69M Sell
54,958
-3,660
-6% -$345K 0.44% 58
2021
Q1
$4.9M Buy
58,618
+2,531
+5% +$214K 0.4% 69
2020
Q4
$5.12M Buy
56,087
+4,549
+9% +$377K 0.47% 65
2020
Q3
$4.11M Buy
51,538
+403
+0.8% +$31.4K 0.47% 60
2020
Q2
$3.53M Buy
51,135
+2,076
+4% +$148K 0.44% 65
2020
Q1
$3.08M Buy
49,059
+2,544
+5% +$183K 0.47% 59
2019
Q4
$3.62M Sell
46,515
-195
-0.4% -$15.2K 0.43% 67
2019
Q3
$3.42M Sell
46,710
-17,913
-28% -$1.26M 0.46% 67
2019
Q2
$3.98M Buy
64,623
+3,483
+6% +$211K 0.54% 53
2019
Q1
$3.9M Sell
61,140
-18,723
-23% -$1.07M 0.56% 50
2018
Q4
$4.08M Buy
+79,863
New +$4.04M 0.61% 43
2017
Q1
– Sell
-35,952
Closed -$1.12M – 243
2016
Q4
$1.12M Buy
+35,952
New +$1.16M 0.18% 148

Other funds holding EW

Calamos Wealth Management's EW Position: Q3 2026 in Review

Calamos Wealth Management increased its Edwards Lifesciences (EW) stake by 6.1% in Q3 2026, buying an estimated $12.5K and bringing the position to 2,438 shares worth $210K. The position accounts for 0.01% of the portfolio, ranked #447.

Calamos Wealth Management first reported a position in EW in Q4 2016 and has held it in 27 quarters since. The position peaked at $7.37M in Q4 2021. 1,342 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Calamos Wealth Management held 2,438 shares of Edwards Lifesciences worth $210K as of Q3 2026.
  • Calamos Wealth Management bought 141 Edwards Lifesciences shares in Q3 2026, an estimated $12.5K.
  • Edwards Lifesciences made up 0.01% of Calamos Wealth Management's portfolio in Q3 2026, its #447 holding.
  • Calamos Wealth Management first reported a position in Edwards Lifesciences in Q4 2016 and has held it in 27 quarters since.
  • Calamos Wealth Management's Edwards Lifesciences position peaked at $7.37M in Q4 2021.
  • 1,342 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Calamos Wealth Management's 13F filing for Q3 2026, filed 2 Nov 2026.